{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PARP+Inhibitor&page=7",
    "query": {
      "condition": "PARP Inhibitor",
      "page": 7
    },
    "page_size": 10
  },
  "pagination": {
    "page": 7,
    "page_size": 10,
    "total_count": 187,
    "total_pages": 19,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PARP+Inhibitor&page=8&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=PARP+Inhibitor&page=6&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-15T10:21:36.813Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04367467",
      "title": "Effect of PARP Inhibitors on Glomerular Filtration Rate",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Solid Tumor",
        "Ovarian Cancer",
        "Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Kidney Function Test",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 2,
      "start_date": "2020-02-03",
      "completion_date": "2021-07-01",
      "has_results": false,
      "last_update_posted_date": "2022-01-26",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04367467"
    },
    {
      "nct_id": "NCT01905592",
      "title": "A Phase III Trial of Niraparib Versus Physician's Choice in HER2 Negative, Germline BRCA Mutation-positive Breast Cancer Patients",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Neoplasms, Breast",
        "Carcinoma of Breast",
        "Human Epidermal Growth Factor 2 Negative Carcinoma of Breast",
        "BRCA1 Gene Mutation",
        "BRCA2 Gene Mutation",
        "Ovarian Neoplasms"
      ],
      "interventions": [
        {
          "name": "niraparib",
          "type": "DRUG"
        },
        {
          "name": "Physician's choice",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Tesaro, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 216,
      "start_date": "2014-02-25",
      "completion_date": "2021-10-26",
      "has_results": true,
      "last_update_posted_date": "2022-11-15",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 25,
      "location_summary": "Tucson, Arizona • Los Angeles, California • Fort Myers, Florida + 20 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Fort Myers",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01905592"
    },
    {
      "nct_id": "NCT00494234",
      "title": "Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Breast Neoplasms"
      ],
      "interventions": [
        {
          "name": "Olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 130 Years · Female only"
      },
      "enrollment_count": 54,
      "start_date": "2007-06-15",
      "completion_date": "2022-12-21",
      "has_results": true,
      "last_update_posted_date": "2024-01-19",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 2,
      "location_summary": "West Hollywood, California • Boston, Massachusetts",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00494234"
    },
    {
      "nct_id": "NCT01749397",
      "title": "Veliparib and Floxuridine in Treating Patients With Metastatic Epithelial Ovarian, Primary Peritoneal Cavity, or Fallopian Tube Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Stage IV Fallopian Tube Cancer AJCC v6 and v7",
        "Stage IV Ovarian Cancer AJCC v6 and v7",
        "Stage IV Primary Peritoneal Cancer AJCC v7"
      ],
      "interventions": [
        {
          "name": "Floxuridine",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 29,
      "start_date": "2012-12-07",
      "completion_date": "2019-11-21",
      "has_results": false,
      "last_update_posted_date": "2020-07-02",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 5,
      "location_summary": "Scottsdale, Arizona • Baltimore, Maryland • Rochester, Minnesota + 1 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01749397"
    },
    {
      "nct_id": "NCT04701307",
      "title": "Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Lung Small Cell Carcinoma",
        "Neuroendocrine Carcinoma",
        "Stage III Lung Cancer AJCC v8",
        "Stage IIIA Lung Cancer AJCC v8",
        "Stage IIIB Lung Cancer AJCC v8",
        "Stage IIIC Lung Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Dostarlimab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 48,
      "start_date": "2021-02-01",
      "completion_date": "2027-04-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-07",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04701307"
    },
    {
      "nct_id": "NCT02163694",
      "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Veliparib Placebo",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 513,
      "start_date": "2014-04-08",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 56,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163694"
    },
    {
      "nct_id": "NCT01078662",
      "title": "Open Label Study to Assess Efficacy and Safety of Olaparib in Confirmed Genetic BRCA1 or BRCA2 Mutation Pats",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Ovarian",
        "Breast",
        "Prostate",
        "Pancreatic",
        "Advanced Tumours"
      ],
      "interventions": [
        {
          "name": "olaparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 298,
      "start_date": "2010-02-21",
      "completion_date": "2024-08-12",
      "has_results": true,
      "last_update_posted_date": "2025-08-13",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 2,
      "location_summary": "West Hollywood, California • Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "West Hollywood",
          "state": "California"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01078662"
    },
    {
      "nct_id": "NCT01399840",
      "title": "Study of BMN 673, a PARP Inhibitor, in Patients With Advanced Hematological Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Acute Myeloid Leukemia",
        "Myelodysplastic Syndrome",
        "Chronic Lymphocytic Leukemia",
        "Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "BMN 673",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 33,
      "start_date": "2011-06-30",
      "completion_date": "2014-05-31",
      "has_results": false,
      "last_update_posted_date": "2017-09-15",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 3,
      "location_summary": "Indianapolis, Indiana • Seattle, Washington • Madison, Wisconsin",
      "locations": [
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        },
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01399840"
    },
    {
      "nct_id": "NCT06161493",
      "title": "ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Ovarian Cancer",
        "Recurrent Solid Tumors"
      ],
      "interventions": [
        {
          "name": "ZEN003694",
          "type": "DRUG"
        },
        {
          "name": "Niraparib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Haider Mahdi",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 0,
      "start_date": "2024-01-23",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2024-10-15",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 1,
      "location_summary": "Pittsburgh, Pennsylvania",
      "locations": [
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06161493"
    },
    {
      "nct_id": "NCT02769962",
      "title": "Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Urothelial Carcinoma",
        "Urothelial Cancer",
        "Lung Neoplasms",
        "Small Cell Lung Cancer",
        "Prostate Cancer"
      ],
      "interventions": [
        {
          "name": "EP0057",
          "type": "DRUG"
        },
        {
          "name": "olaparib",
          "type": "DRUG"
        },
        {
          "name": "CT scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "CT chest, abdomen, and pelvis",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Bone scan",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "ECG",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Echocardiogram",
          "type": "DIAGNOSTIC_TEST"
        },
        {
          "name": "Biopsy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "DIAGNOSTIC_TEST",
        "PROCEDURE"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2016-05-09",
      "completion_date": "2025-03-04",
      "has_results": true,
      "last_update_posted_date": "2026-08-13",
      "last_synced_at": "2026-11-15T10:21:36.813Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02769962"
    }
  ]
}